Texas Permanent School Fund Corp Reduces Stock Position in REGENXBIO Inc. (NASDAQ:RGNX)

Texas Permanent School Fund Corp lowered its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 14.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,292 shares of the biotechnology company’s stock after selling 4,912 shares during the quarter. Texas Permanent School Fund Corp owned 0.06% of REGENXBIO worth $354,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of RGNX. PNC Financial Services Group Inc. raised its position in REGENXBIO by 73.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 746 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in REGENXBIO during the 1st quarter valued at $56,000. Headlands Technologies LLC raised its position in REGENXBIO by 276.8% during the 1st quarter. Headlands Technologies LLC now owns 3,828 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 2,812 shares in the last quarter. Diversified Trust Co bought a new stake in REGENXBIO during the 2nd quarter valued at $121,000. Finally, Arizona State Retirement System raised its position in REGENXBIO by 20.6% during the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 1,997 shares in the last quarter. 88.08% of the stock is owned by institutional investors.

REGENXBIO Price Performance

Shares of RGNX stock opened at $11.69 on Friday. REGENXBIO Inc. has a 1-year low of $10.49 and a 1-year high of $28.80. The stock’s fifty day moving average price is $12.52 and its 200 day moving average price is $15.00. The company has a market cap of $575.80 million, a price-to-earnings ratio of -1.99 and a beta of 1.22.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.24. REGENXBIO had a negative return on equity of 68.21% and a negative net margin of 270.74%. The firm had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.97 million. During the same period in the previous year, the business earned ($1.66) EPS. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. As a group, equities research analysts anticipate that REGENXBIO Inc. will post -4.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RGNX has been the subject of a number of research analyst reports. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday. Barclays reduced their price target on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. The Goldman Sachs Group initiated coverage on REGENXBIO in a research report on Friday, June 7th. They issued a “buy” rating and a $38.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $39.00 price target on shares of REGENXBIO in a research report on Wednesday, September 4th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.91.

Insider Buying and Selling

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $11.27, for a total transaction of $112,700.00. Following the sale, the director now owns 11,286 shares in the company, valued at approximately $127,193.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other REGENXBIO news, CEO Curran Simpson sold 9,648 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $15.04, for a total transaction of $145,105.92. Following the sale, the chief executive officer now owns 170,137 shares in the company, valued at approximately $2,558,860.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $11.27, for a total value of $112,700.00. Following the sale, the director now owns 11,286 shares in the company, valued at approximately $127,193.22. The disclosure for this sale can be found here. Insiders have sold a total of 65,279 shares of company stock worth $875,634 in the last ninety days. 13.13% of the stock is owned by insiders.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.